KORU Medical Systems, Inc. (KRMD)

Over the past six months, KORU Medical Systems' stock has experienced significant positive movement, with a 46.67% increase from November 1, 2024, to October 31, 2025, and a 55.04% increase over the last year. Recent positive stock events include the Q3 2025 earnings report, where KORU Medical reported revenue exceeding $10 million (27% year-over-year growth), surpassing forecasts and leading to a 2.41% stock increase in aftermarket trading. International revenue surged by 230%, offsetting a 5% domestic decline, and the company achieved positive adjusted EBITDA and cash flow, reducing net losses by 50% to $2.2 million. Management also raised full-year revenue guidance to $40.5-$41 million, targeting over 20% growth for 2026, and expects FDA submission for oncology market entry by Q1 2026. Other news that may have impacted the stock include presentations at medical symposiums and participation in investor conferences in November 2025.

The demand for KORU Medical Systems' products and services is likely to be relatively stable throughout the year rather than exhibiting significant seasonality, due to the nature of its business, which focuses on providing life-saving therapies for chronic illnesses. These conditions require ongoing treatment, suggesting a consistent need for the company's infusion systems and related products. While stock price seasonality has been observed, this does not directly reflect the seasonality of product demand.

KORU Medical Systems, Inc. is a medical technology company specializing in subcutaneous infusion solutions for patients with chronic illnesses. The company designs, manufactures, and commercializes proprietary portable and advanced medical devices primarily for the subcutaneous drug delivery market, focusing on home and specialty infusion solutions. Its major products include the FREEDOM Infusion Systems, such as the FREEDOM60® and FreedomEdge® syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

KORU Medical Systems, Inc. develops, manufactures, and commercializes its subcutaneous infusion solutions for the United States and international markets. The company has been actively expanding its international business.

KORU Medical Systems has maintained a generally positive standing, as indicated by analyst ratings, receiving a consensus rating of "Moderate Buy" from Wall Street analysts. A notable event impacting its reputation was a successful appeal in April 2024 related to an ongoing audit by its EU notified body, The British Standards Institute (BSI). The appeal upheld the company's position against a recommendation for non-certification, ensuring no interruption of product sales in the EU and maintaining the certification of its products.

KORU Medical Systems, Inc. has a diverse ownership structure. Retail investors held the largest share at 36%, while institutions held 32% and hedge funds owned 24% of the shares as of March 30, 2024. Major institutional owners and shareholders include First Light Asset Management, LLC, Topline Capital Management, LLC, Vanguard Group Inc, BlackRock, Inc., Geode Capital Management, LLC, Meros Investment Management, LP, and Archon Capital Management LLC. Other notable institutional holders include Horton Capital Partners Fund, L.P., JPMorgan Chase & Co., and Goldman Sachs Group Inc. Insiders collectively own approximately 20.60% of the company's stock.